NasdaqCM - Nasdaq Real Time Price USD

InspireMD, Inc. (NSPR)

Compare

2.7243

-0.0557

(-2.00%)

At close: 4:00:00 PM EST

2.7600

+0.04

+(1.31%)

After hours: 4:28:00 PM EST

Here's Why We're Watching InspireMD's (NASDAQ:NSPR) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Simply Wall St. 3 days ago

NSPR
-2.00%
InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025

MIAMI, Dec. 12, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that Craig Shore, Chief Financial Officer, has decided to retire from the Company after a successor CFO is identified and appointed. Mr. Shore will remain as CFO until his successor is appointed and will assist in a smooth and orderly transition. Marvin Slosman, Chief Executive Officer of InspireMD, commented, “Craig

GlobeNewswire last month

NSPR
-2.00%
InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

Study represents a significant step forward in Company’s mission to serve the broadest set of physician and patient needs with best-in-class CAS and TCAR solutionsMIAMI, Dec. 09, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the first patient has been enrolled in the company’s CGUARDIANS II clinical trial evaluating its CGuard Prime Carotid Stent System in patients undergo

GlobeNewswire last month

NSPR
-2.00%
InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE: ABT) in April 2023. Paul Stuka, Chairman of the Board of InspireMD, sta

GlobeNewswire last month

NSPR
-2.00%
ABT
InspireMD Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.15 loss in 3Q 2023)

InspireMD ( NASDAQ:NSPR ) Third Quarter 2024 Results Key Financial Results Revenue: US$1.81m (up 16% from 3Q 2023). Net...

Simply Wall St. 2 months ago

NSPR
-2.00%
InspireMD Inc (NSPR) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Rising Costs and ...

InspireMD Inc (NSPR) reports a 16.3% revenue increase while navigating higher expenses and gearing up for a pivotal U.S. market entry.

GuruFocus.com 2 months ago

NSPR
-2.00%
InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update

– Submitted a Premarket Approval (PMA) application to the FDA seeking marketing approval of the CGuard Prime carotid stent system in the U.S. – – Announced approval of an IDE application to initiate the CGUARDIANS II pivotal study of the CGuard Prime carotid stent system for use during TCAR procedures – – Established its Headquarters in Miami, Florida, to optimally support the anticipated U.S. commercial launch of CGuard Prime in H1 2025, if approved – Achieved another record high revenue and un

GlobeNewswire 2 months ago

NSPR
-2.00%
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIAMI, Nov. 08, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to five new non-executive employees in the aggregate amount of 197,167 shares of restricted stock outside of InspireMD’s 2021 Equity Compensation Plan, with a grant date as of October 24, 2024, as an inducement material to the employee

GlobeNewswire 2 months ago

NSPR
-2.00%
InspireMD to Report Third Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, November 12th

-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel and MIAMI, Nov. 04, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report third quarter 2024 financial results on Tuesday, November 12th, 2024, before the financial markets open. Management will host a conference call and webcast with the investment comm

GlobeNewswire 2 months ago

NSPR
-2.00%
One InspireMD Insider Raised Stake By 13% In Previous Year

Insiders were net buyers of InspireMD, Inc.'s ( NASDAQ:NSPR ) stock during the past year. That is, insiders bought more...

Simply Wall St. 2 months ago

NSPR
-2.00%
InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

MIAMI, Oct. 15, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the establishment of its global headquarters in Miami, Florida. The new facility will ideally position the Company to support the anticipated U.S. launch and commercialization of the CGuard Prime carotid stent system in the first half of 2025, if approved. Marvin Slosman, Chief Executive Officer of InspireMD, stated,

GlobeNewswire 3 months ago

NSPR
-2.00%
InspireMD Advances with FDA Study Approval and Global Goals

An update from InspireMD ( (NSPR) ) is now available. InspireMD, Inc. announced on October 7, 2024, the FDA approval to begin the CGUARDIANS II pivotal study for their CGuard Prime 80cm Carotid Stent System. This milestone is a significant step for the company, aiming to enhance stroke prevention and carotid disease management. The study, led by esteemed vascular surgeons Dr. Patrick Geraghty and Dr. Patrick Muck, will evaluate the device’s use during transcarotid revascularization procedures. T

TipRanks 3 months ago

NSPR
-2.00%
InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

MIAMI, Oct. 07, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational Device Exemption (IDE) Application to initiate the CGUARDIANS II pivotal study of its CGuard Prime 80cm Carotid Stent System during transcarotid revascularization (TCAR) procedures. In February 2024, InspireMD announced that P

GlobeNewswire 3 months ago

NSPR
-2.00%
InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

PMA based on overwhelmingly positive results from the pivotal C-GUARDIANS clinical study that were first presented at LINC 2024 in May U.S. commercial launch anticipated in H1 2025, if approved TEL AVIV, Israel and MIAMI, Sept. 16, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that it has submitted a Premarket Approval (PMA) application to the U.S. Food and Drug Administration

GlobeNewswire 3 months ago

NSPR
-2.00%
Investors in InspireMD (NASDAQ:NSPR) have unfortunately lost 88% over the last five years

Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see...

Simply Wall St. 4 months ago

NSPR
-2.00%
Companies Like InspireMD (NASDAQ:NSPR) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 5 months ago

NSPR
-2.00%
InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

- Announced positive outcomes from the C-GUARDIANS IDE clinical trial of the CGuard™ Prime carotid stent system demonstrating a one-year primary endpoint event rate of 1.95%, the lowest for any carotid stent or embolic protection device pivotal trial – - On track to submit a Premarket Approval (PMA) application to the FDA this quarter - - Raised gross proceeds of $17.9 million from full exercise of Series H warrants triggered by announcement of C-GUARDIANS data - --Management to host investor co

GlobeNewswire 5 months ago

NSPR
-2.00%
InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

CGuard was the only investigational carotid stent approved by FDA for inclusion in the trials CREST-2 included 23 cases implanted with CGuard TEL AVIV, Israel and MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today congratulated the lead investigators on the completion of enrollment in the CREST-2 (Carotid Revascularization Endarterectomy or Stenting Trial) clinical trials. The

GlobeNewswire 5 months ago

NSPR
-2.00%
InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, and MIAMI, July 30, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report second quarter 2024 financial results on Tuesday, August 6th, before the financial markets open. Management will host a conference call and webcast with the investment community a

GlobeNewswire 5 months ago

NSPR
-2.00%
InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million

Series H warrants exercisable following release of positive outcomes results related to one-year follow-up from the Company’s C-GUARDIANS pivotal trial. Participating warrant holders include Marshall Wace, OrbiMed, Rosalind, Nantahala, Soleus, Velan, and certain InspireMD Board members. Represents first of four milestone-driven warrant tranches pursuant to private placement financing of up to $113.6 million announced in May 2023. TEL AVIV, Israel and WESTIN, Fla., July 01, 2024 (GLOBE NEWSWIRE)

GlobeNewswire 6 months ago

NSPR
-2.00%

Performance Overview

Return	NSPR	S&P 500
YTD	+3.19%	+1.52%
1-Year	-10.97%	+25.82%
3-Year	-6.70%	+28.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

InspireMD, Inc. (NSPR)

Here's Why We're Watching InspireMD's (NASDAQ:NSPR) Cash Burn Situation

InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

InspireMD Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.15 loss in 3Q 2023)

InspireMD Inc (NSPR) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Rising Costs and ...

InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

InspireMD to Report Third Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, November 12th

One InspireMD Insider Raised Stake By 13% In Previous Year

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

InspireMD Advances with FDA Study Approval and Global Goals

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

Investors in InspireMD (NASDAQ:NSPR) have unfortunately lost 88% over the last five years

Companies Like InspireMD (NASDAQ:NSPR) Are In A Position To Invest In Growth

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million

Performance Overview